Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer

Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma

The identification of cancer stem cells (CSCs) has improved the understanding of tumor occurrence and development. According to CSC theory, colorectal carcinoma (CRC) may be derived from these few cells. Thus, markers for CSCs may lead to the identification of CSCs and investigation of the correlation with various clinicopathological features and survival time in human CRC patients. Aldehyde de...

Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma

Cancer stem cells (CSCs) are unique subpopulations that have the capacity to drive malignant progression with renewal abilities. Recently the role of some of CSCs in gastric adenocarcinoma has been studied. This study was performed in order to evaluate CD44 and CD133 expressions by immunohistochemistry in 95 primary gastric adenocarcinoma and their relation to clinical and pathological paramete...

Association of CD166 expression with clinicopathologic characteristics of colorectal cancer

بررسی بیان شاخص‌های بنیادینگی ALDH1 و CD133 در رده‌های سلولی ملانوما A375 و D10

Background: The cancer stem cells (CSCs) are involved in invasion and metastasis of melanoma, the most lethal and aggressive form of skin cancer. In the present study, the expression of putative stem cell markers CD133 and ALDH1 were evaluated in melanoma cell lines and then the cells sorted based on the expression of these markers. Methods: In the present study expression of CD133 and A...

Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer

PURPOSE CD133 and aldehyde dehydrogenase 1 (ALDH1) expression are reliable poor-prognosis markers associated with the presence of adverse biomarkers and subtypes of breast cancer. The aim of our study was to investigate and compare the clinical impact of CD133 and ALDH1 expression in invasive breast cancer. METHODS A total of 291 consecutive patients with invasive breast cancer who underwent ...